Cell therapy in renal cell carcinoma;Thérapie cellulaire et cancer du rein

Bulletin du Cancer

Volumn 90, Issue 8-9, 2003, Pages 711-721

  Ravaud, Alain ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Cellular therapy; Renal cell carcinoma

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CANCER THERAPY; CELL SPECIFICITY; CLINICAL EXAMINATION; CYTOTOXICITY; DENDRITIC CELL; EVOLUTION; IMMUNOCOMPETENCE; IN VITRO STUDY; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGEN-PRESENTING CELLS; CARCINOMA, RENAL CELL; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGE ACTIVATION; MACROPHAGES;

EID: 0141922134     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Ravaud A. Thérapie cellulaire. Bull Cancer 2001; 88: 91-100.
2. Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichlmayr R, Koch KM, et al. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997; 11: 255-8.
3. Mitropoulos D, Koui S, Rodriguez-Villanueva J, Platsoucas CD. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived cell lines from patients with renal cell carcinoma. Clin Exp Immunol 1994; 97: 321-7.
4. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorrevits L, Van Damme B, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumor-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997; 109: 501-9.
5. Puisieux I, Bain C, Merrouche Y, Malacher P, Kourilsky P, Even J, et al. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma : relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 1996; 66: 201-8.
6. Caignard A, Guillard M, Gaudin M, Escudier B, Treibel F, Dietrich PY. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 1996; 66: 564-70.
7. McCune CS, O'Donnel RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990; 32: 62-6.
8. Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother Emphas Tumor Immunol 1996; 19: 364-74.
9. Galligioni E, Quaia M, Carbone A, Spada A, Favaro D, Santarosa M, et al. Adjuvant immunotherapy treatment of renal cell carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin : five-year results of a prospective randomized trial. Cancer 1996; 77: 2560-6.
10. Logan TF, Banner B, Rao U, Ernsroff MS, Wommark N, Whiteside TL, et al. Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol 1998; 114: 347-54.
11. Knoefel F, Nuske K, Steiner T, Junker K, Koesmehl H, Rebstock K, et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-β1 in primary cultures and modulate T lymphocyte blast transformarion. J Interferon Cytokine Res 1997; 17: 95-102.
12. Blay JY, Négrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
13. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, et al. Host immune response in renal cell cancer : interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995; 41: 111-21.
14. + T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993; 150: 114-23.
15. Schendel DJ, Gansbacher B, Oberneder R, Kreigmair M, Hofstetter A, Reithmuller G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151: 4209-20.
16. Brouwenstijn N, Hoogstraten C, Verdegaal EM, Van der Speck CW, Mulder A, Osanto S, et al. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer 1996; 68: 177-82.
17. Brouwenstijn N, Gaugler B, Kruse KM, Van der Spek CW, Deckers JG, Mulder A, et al. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma. J Immunother 1998; 21: 427-34.
18. Neumann E, Engelberg A, Decker J, Storkel S, Jaeger E, Huber C, et al. Heterogeneous expression fo the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma : candidates for T-cell-based immunotherapies? Cancer Res 1998; 58: 4090-5.
19. Guagler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Speck CW, Patard JJ, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal cell carcinoma. Immunogenetics 1996; 44: 323-30.
20. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, et al. Her-2/neu-derived peptide are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732-6.
21. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-9.
22. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp-70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999; 162: 1730-8.
23. Brakenhoff RH, Knippels EM, Van Dongen GA. Optimization and simplification of expression clonin in eukaryotic/vector systems. Anal Biochem 1994; 218: 460-3.
24. Opavksy R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family : structure and exon to protein domain relationships. Genomics 1996; 33: 480-7.
25. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-94.
26. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinoma. Br J Cancer 1999; 81: 741-6.
27. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Ooesterwijk E, Figdor CG, et al. The renal cell carcinoma-associated antigen G 250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic lymphocytes. Cancer Res 1999; 59: 5554-9.
28. Grabmaier K, Vissers JL, De Weijert MC, Ooesterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85: 865-70.
29. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells : lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 1984; 44: 1946-53.
30. Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells : analysis of progenitors and effectors. J Exp Med 1986; 164: 1193-205.
31. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon : relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-25.
32. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB. A new approach to generating antitumor effects for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res 1988; 48: 3461-9.
33. Liao NS, Bix M, Zijlstra M, Jaenisch R, Rauler D. MHC class I deficiency : susceptibility to natural killer (NK) cells and impaired NK activity. Sciene 1991; 253: 199-202.
34. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000; 21: 420-2.
35. Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 1996; 56: 826-30.
36. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487-9.
37. Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 1985; 135: 646-52.
38. Lafrenière R, Rosenberg SA. Adoprive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and nonimunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135: 4273-80.
39. Papa MZ, Mulé JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo : successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res 1986; 46: 4973-8.
40. Rosenberg SA, Lorze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161: 1169-88.
41. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-92.
42. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-485
43. Mc Cabe M, Stablein D, Hawkins MJ. The modified group C experience-phase III randomized trials of IL2 versus IL2/LAK in advanced renal cell cancer and advanced melanoma. Proc Am Soc Clin Oncol 1991; 10: 213 (abstract).
44. Palmer PA, Vinke J, Evers P, Pourreau C, Oskam R, Roest G, et al. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 1992; 28A: 1038-44.
45. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992; 10: 960-8.
46. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion interleukin 2 or bolus injection interleukin 2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275-81.
47. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, Oconnell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-32.
48. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-32.
49. Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F, et al. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells : improvement of clinical response in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 1994; 30A: 1078-83.
50. Fidler IJ. Inhibition of pulmonary metastases by intravenous injection of specifically activated macrophages. Cancer Res 1974; 34: 1074-8.
51. Le J, Prensky W, Yip YK, Chang Z, Hoffman T, Stevenson HC, et al. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol 1983; 131: 2821-6.
52. Chokri M, Freudenberg M, Galanos C, Poindron P, Bartholeyns J. Compared antitumoral effects of LPS, TNF, IFNγ and activated macrophages on experimental tumors. Synergism and tissue distribution. Anticancer Res 1989; 9: 1185-90.
53. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser HG, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes : a new approach to cancer immunotherapy. Cancer Res 1990; 50: 2228-36.
54. Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML, et al. Phase I trial of intravenous infusion of ex vivo activated autologous blood-derived macrophages in patients with non-small-cell lung cancer : toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991; 33: 319-26.
55. Lopez M, Fechtenbaum J, David B, Martinache C, Chokri M, Canepa S, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients : a pilot study. J Immunother 1992; 11: 209-17.
56. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. J Exp Med 1996; 184: 695-706.
57. Szabolcs P, Avigan D, Gezelter S, Ciocon DH, Moore MA, Steinman RM, et al. Dendritic cells and macrophages can mature indepently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 1996; 87: 4520-30.
58. Lesimple T, Moisan A, Guillé F, Leberre C, Audran R, Drenou B, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 2000; 23: 275-9
59. Brunner KT, McDonald HR, Cerottini JC. Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors. J Exp Med 1981; 154: 362-73.
60. Chapdelaine JM, Plata F, Lilly F. Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes. J Exp Med 1979; 149: 1531-6.
61. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-25.
62. Koo AS, Tso CL, Shimabukuro T, Peyret C, de Kernion JB, Belldegrun A. Autologous tuot-specific cytotoxicity of tumor infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991; 10: 347-54.
63. + melanoma-infiltrating lymphocytes. Eur J Immunol 1995; 25: 2732-6.
64. + clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol 1992; 22: 1795-802.
65. + T cells. J Exp Med 1999; 189: 757-66.
66. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmullet G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes I, HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151: 4209-20.
67. Spagnoli GC, Schaefer C, Willimann TE, Kochet T, Amoroso A, Juretic A, et al. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp 100 and tyrosinase genes : a study in an unselected group of HLA-A2.1 positive patients. Int J Cancer 1995; 64: 309-15.
68. Robbins PF, El-Gamil M, Li YT, Fitzgerald EB, Kawakami Y, Rosenberg SA. The intronic region of an incompleted spliced gp-100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997; 159: 303-8.
69. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-65.
70. Ronsin C, Chung-Scott V, Pouillion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol 1999; 163: 445-54.
71. Economou JS, Belldegrun AS, Glaspy J, Toloza EM, Figlin R, Hobbs J, et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes : results of a double gene marking trial. J Clin Invest 1996; 97: 515-21.
72. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250-61.
73. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987; 79: 1067-75.
74. Barth RJ Jr, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990; 144: 1531-7.
75. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2 : a pilot study. J Clin Oncol 1988; 6: 839-53.
76. Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51: 4199-205.
77. Markowitz A, Parkinson D, Itoh K, Legha S, von Eshenbach A, Logothetis C, et al. Phase Ib study of tumor infiltrating lymphocytes (TIL) combined with recombinant interferon-alpha 2a (rINF-α), recombinant interleukin-2 (rIL-2) and cyclophosphamide (CYC) in patients with advanced renal cell carcinoma (RCC) and malignant melanoma (MM). Proc Am Soc Clin Ontol 1991; 10: 216 (abst. 726).
78. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma and renal cell carcinoma : a pilot study. J Clin Oncol 1995; 13: 1939-45.
79. Whiteside TL, Jost LM, Heberman RB. Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy. Crit Rev Oncol Hematol 1992; 12: 25-47.
80. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol 1990; 144: 4487-95.
81. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, et al. Loss of T-cell receptor zeta chain and p561ck in T cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-6.
82. + tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521-9.
83. Schecter B, Treves AJ, Feldman M. Specific cytotoxicity in vitro of lymphocytes sensitized in culture against tumor cells. J Natl Cancer Inst 1976; 56: 975-9.
84. Cheever MA, Greenberg PD, Fefer A. Specific of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 1980; 125: 711-4.
85. Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J Immunol 1986; 136: 3891-8.
86. Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization : culture requirements and characterization of immunologic specificity. J Immunol 1988; 140: 2453-61.
87. Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non specifically expanded by culture with interleukin-2. J Immunol 1981; 126: 1318-22.
88. Cheever MA, Thompson DB, Klarnet JP, Greenberg PD. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy and persist long-term as functional memory cells. J Exp Med 1986; 163: 1100-12.
89. Yoshizawa H, Chang AE, Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin-2 activated tumor-draining lymph node cells. Cancer Res 1992; 52: 1129-36.
90. Sawzuck IS. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma. Urol Clin North Am 1990; 20: 297-301.
91. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal carcinoma. Lancet 1990; 335: 994-8.
92. Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW, Alvord WG, et al. Treatment of cancer patients With ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol 1993; 11: 652-60.
93. Graham S, Babayan RK, Lamm DL, Sawczuk I, Ross SD, Lavin PT, et al. The use of ex vivo activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma : final results from a randomized multisite study. Semin Urol 1993; 11: 27-34.
94. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15: 796-807.
95. Lavin PT, Maar R, Franklin M, Ross S, Martin J, Osband ME. Autolymphocyte therapy for metastatic renal cell carcinoma : initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc 1992; 24: 3059-64.
96. Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, et al. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res 1999; 59: 2167-73.
97. Imro MA, Manici S, Russo V, Consogno G, Bellone M, Rugarli C, et al. Major histocompatibility complex class I restricted cytotoxic T cells specific-for natural melanoma peptides recognize unidentified shared melanoma antigen(s). Cancer Res 1999; 59: 2287-91.
98. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162: 2227-34.
99. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001; 91: 749-56.
100. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, et al. Immunoselection in vivo : independant loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL. Int J Cancer 1997; 71: 142-7.
101. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5.
102. Reis-e-Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995; 182: 841-51.
103. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990; 172: 631-64.
104. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
105. Schulet G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-7.
106. Bancheteau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
107. Rissoan MC, Soumelis V, Kadowaki N, Gtouatd G, Briete F, de Waal M, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
108. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med 1995; 182: 283-8.
109. Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987; 166: 1654-67.
110. Coulon V, Ravaud A, Hunt S, Gualde N. In vitro production of human antigen presenting cells issued from bone marrow of patients with cancer. Hematol Cell Ther 1997; 39: 237-44.
111. + progenitors in human bone marrow. J Immunol 1992; 149: 2681-8.
112. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
113. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137-51.
114. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-61.
115. + progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1 (27-35) specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57: 5534-41.
116. + helper T cells. J Exp Med 1990; 171: 1315-32.
117. Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumor-specific Lyt.-1+2-T cells in eradicating tumor cells in vivo. I. Lyt-1+2-T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 1984; 133: 1671-6.
118. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune response in vivo. Nat Med 1999; 5: 405-11.
119. Dubois B, Vanbervliet B, Fayerre J, Massacriet C, Van Kooten C, Briere F, et al. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 1997; 185: 941-51.
120. Mayotdomo JI, Zorina T, Stotkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and thetapeutic antitumour immunity. Nature Med 1995; 1: 1297-302.
121. Nait SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-15.
122. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lorze MT, et al. Therapy of murine tumors with tumor pepride-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-associated cytokines. J Exp Med 1996; 183: 87-97.
123. Albert ML, Sauer B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.
124. Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, et al. A discrete population of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191: 435-43.
125. Sauter B, Albert ML, Francisco L, Latsson M, Sometsan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immuno-stimulatory dendritic cells. J Exp Med 2000; 191: 423-33.
126. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59: 56-8.
127. Thomas R, Chambers M, Boytar R, Barker K, Cavanagh LL, McFayden S, et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intra-dermal injection for melanoma immunotherapy. Melanoma Res 1999; 9: 474-81.
128. Coulon V, Ravaud A, Gaston R, Delaunay MM, Pariente JL, Verdier D, et al. In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. Int J Cancer 2000; 88: 783-90.
129. Girlitz B, Mulders P, Tso CL, Pang S, Dannull J, Kaboo R, et al. Specific antitumor response against human renal cell carcinoma by dendritic cells loaded with tumor antigens. Proc Annu Meet Am Assoc Cancer Res 1997; 38: A 2315.
130. Heiser A, Maurice MA, Yancey D, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulated polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61: 3388-93.
131. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase 1 clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80.
132. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150-6.
133. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nature 1996; 2: 52-8.
134. Timmermann JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune response in 35 patients. Blood 2002; 99: 1517-26.
135. Nestlé FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with pepride-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-32.
136. Hurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage 3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytoroxic T cells and induce regression of some metastasess in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
137. Hinkel A, Gitlitz B, Mulders P, Moldawer N, Tso C, Kaboo R, et al. Dendritic cell therapy for metastatic renal cell carcinoma: a translational phase I clinical trial. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A 1665.
138. Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M. CD83 + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 1998; 352: 1358.
139. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513-9.
140. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, et al. Effective tumor vaccine generated by fusion and hepatoma cells with activated B cells. Science 1994; 263: 518-20.
141. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997; 3: 558-61.
142. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2000; 6: 332-6.
143. Tuffs A. Doubts raised over cancer vaccine study. Br Med J 2001; 323: 184.
144. Unanue ER. The regulatory role of macrophages in antigenic stimulation. Part two: symbiotic relationship between lymphocytes and macrophages. Adv Immunol 1981; 31: 1-136.
145. Yewdell JW, Bennink JR. The binary logic of antigen processing and presentation to T cells. Cell 1990; 62: 203-6.
146. Adams DO, Hamilton TA. The cell biology of macrophages activation. Annu Rev Immunol 1984; 2: 283-318.
147. Lipcomb MF, Lyons CR, Nunez G, Ball EJ, Stastny P, Vial W, et al. Human alveolar macrophages: HLA-DR-positive macrophages that are poor stimulators of a primary mixed teukocyte reaction. J Immunol 1986; 136: 497-504.
148. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Beelen RH. Antigen-presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis. Clin Exp Immunol 1993; 94: 377-84.
149. King PD, Katz DR. Mechanisms of dendritic cell function. Immunol Today 1990; 11: 206-11.
150. Crow MK, Kunkel HG. Human dendritic cells: major stimulators of the autologous and allogeneic mixed leucocyte reactions. Clin Exp Immunol 1982; 49: 338-46.
151. Toujas L, Delcros JG, Diez E, Gervois N, Semana G, Corradin G, et al. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptide. Immunology 1997; 91: 635-42.
152. Rock KL, Rothstein L, Gamble S, Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class 1 MHC molecules. J Immunol 1993; 150: 438-46.
153. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. J Exp Med 1996; 184: 695-706.
154. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed wtih tumor extracts. Int J Cancer 1997; 70: 706-15.
155. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effects of graft-versus-host disease in human recipients of allogenic-marrow grafts. N Engl J Med 1979; 300: 1068-73.
156. Slavin S, Naparstek E, Nagler A, Acketstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-204.
157. Moscovitch M, Slavin S. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 1997; 71: 59-63.
158. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, et al. Evidence of graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-8.
159. Giralt S, Estey E, Albirar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia wirhout myeloablative chemotherapy. Blood 1997; 89: 4531-6.
160. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
161. Hu HS, Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic stem cell transplantation for metastatic renal cell cancer after non-myeloablative chemotherapy: updated results from the University of Chicago. Proc Am Ass Clin Oncol 2002; 21: A 718.
162. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, et al. Non myeloablative conditioning followed by hemaropoietic call allografting and donor lymphocyte infusions for patients with metastatic renal and beast cancer. Blood 2002; 99: 4234-6.
163. Pedrazzoli P, da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-15.